U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07389031) titled 'Maralixibat for Intrahepatic Cholestasis of Pregnancy' on Jan. 26.
Brief Summary: An open label phase 2a/b trial of maralixibat in patients with Intrahepatic Cholestasis of Pregnancy (ICP) and elevated serum bile acid concentrations (sBA) to evaluate safety and tolerability
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Intrahepatic Cholestasis of Pregnancy
Intervention:
DRUG: Maralixibat
Oral solution, dose-titrated. Maralixibat is an ileal bile acid transporter (IBAT) inhibitor.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Imperial College London
Published by HT Digital Content Services with permissio...